Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM13 in R/R CD30+ PTCL or Transformed Mycosis Fungoides
NCT04101331Phase 2Completed
- Sponsor
- Affimed
- Start
- Nov 2019
- Primary completion
- May 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of acimtamig in peripheral T-cell lymphoma (PTCL), mycosis fungoides (MF), sponsored by Affimed. Started Nov 2019; status: completed.
02
Drugs
acimtamig
03
Conditions
peripheral T-cell lymphoma (PTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT04101331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101331.